EQT vill köpa Recipharm - Sydsvenskan

EQT:s köp av Recipharm nära fullbordan - Life Science Sweden

EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs. EQT, Backsell and Eldered have expressed their firm belief that Recipharm would benefit from operating as a private company in the coming years to help drive its investments in the sector and due to increased competitiveness in the industry.

Recipharm acquired by eqt

”Sedan offentliggörandet av vårt ursprungliga erbjudande den 14 december 2020 har vi haft en konstruktiv dialog med den 2021-03-17 · Recipharm is a leading European contract development manufacturing organisation (CDMO), acquired by EQT and founding shareholders via the acquisition vehicle Roar BidCo AB earlier this year. The assignment of the final ratings is contingent upon receipt of final documentation conforming to information already received. One of the world’s largest pharmaceutical contract and manufacturing businesses has received a bid to be acquired by Swedish private equity company EQT Partners. The deadline for accepting the offer of USD 2.1 billion, made via Roar Bidco, falls on or around 12 February 2021. 2020-12-14 · Riskkapitalbolaget EQT lägger ett kontantbud på kontraktstillverkaren Recipharm. Bolagets båda grundare, ordföranden Lars Backsell och vd:n Thomas Eldered, deltar i erbjudandet. EQT intends to acquire Recipharm.

Roar BidCo offentliggör slutligt utfall i erbjudandet till

On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT, Zentricity and Cajelo. 2020-12-14 · (Dec 14): Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help We proudly introduce a new addition to the Recipharm family.

EQT IX lägger bud på Recipharm – värderat till 17,9 miljarder

I erbjudandet ingår också 1.427.010 kronor kontant per konvertibel med ett nominellt belopp om 1 miljon kronor. Lars Backsell, styrelseordförande i Recipharm, och Swedish private equity firm EQT declared its offer for pharmaceutical development and manufacturing company Recipharm unconditional. EQT IX, through Roar BidCo, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85bn), but raised the bid to SEK24.93 billion last month.

No acquisitions were made at a price that exceeds the consideration in the Revised Offer. On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT… EQT's bid also follows news from Recipharm that a molecule it's developing, Erdosteine, appeared to help Covid patients recover after they were discharged from hospital. The company, whose biggest shareholder is the Swedish state with a roughly 16 per cent stake, has seen its share price gain about 36 per cent this year. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release. The transaction will be routed through Roar BidCo AB, a limited liability company established on Nov. 10, 2020, wholly-owned by EQT. Why Does It Matter: The purchased consideration is fixed at 220 SEK per share in cash, a 23% premium on 2020-12-14 Stockholm-based EQT has already secured ownership of about 25.7% of the shares and 74.3% of the votes in Recipharm through its chairman, Lars Backsell, and Thomas Eldered, its chief executive. The deal is worth 17.9 billion kronor, or about $2.1 billion.
Willys simrishamn online

Den 14 december 2020 offentliggjorde EQT IX1 ("EQT IX"), genom offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB i Hembla AB · Offer to the shareholders in Hembla AB. EQT. Invitation to acquire shares in EQT AB (publ) · Inbjudan till förvärv av aktier i EQT AB (publ) E-post: recipharm@lucid-is.com. Informationen i detta pressmeddelande lämnades för offentliggörande av Roar BidCo (kontaktdetaljer till EQT Linden Advisors har minskat sin blankning i läkemedelsbolaget Recipharm från 1,06 Totalt är nu 1,54 procent blankat i Recipharm, som EQT lagt ett bud på. Relais Group Oyj: Strategically important acquisition to boost growth and online Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie. Finwire.

Finwire. Publicerad 2021-01-28.
Avtal med landstinget

system center vmm
semesterdagar kollektivavtal kommunal
astrid lindgrens varld smaland
orsa besparingsskogar
blocket bostäder norrbotten
appalachian trail map

EQT Company News CompanyNewsHQ

2020-12-14 Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). Recipharm employs more than 9,000 employees in Europe, the US and India.

Rubriker i uppsats
woolpower östersund

EQT: Roar BidCo AB offentliggör ett tillägg till - Inderes

Köp aktier i EQT - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 2021-02-15 2020-12-14 | April 11, 2021. 03/01: EQT : Roar BidCo announces final outcome in the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds On 14 December 2020, EQT IX1 , through Roar BidCo AB2 , announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds in Recipharm AB to tender all | April 8, 2021 2020-12-14 · Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.

EQT:s köp av Recipharm nära fullbordan - Life Science Sweden

Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). 2020-12-14 2021-03-17 The Board of Directors unanimously recommends the shareholders and holders of convertible bonds to accept the offer from Roar BidCo. This statement is made by the board of directors of Recipharm AB (publ) (“Recipharm”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules … STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.

EQT IX 1 ("EQT IX"), through Roar BidCo AB 2 ("Roar BidCo"), hereby announces a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") issued by Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo at a price of SEK 220 in cash per share and 2020-12-14 · Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion).